Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AC Immune SA - Common Stock (NQ:ACIU)

2.630 +0.010 (+0.39%)
Delayed Quote Updated: 11:11 AM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AC Immune SA - Common Stock

< Previous 1 2 3 Next >
News headline image
AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune First Half 2026 Financial and Corporate Update
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune First Quarter 2026 Financial and Corporate Updates
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune to Present at the Jefferies 2025 London Healthcare Conference
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
From AC Immune SA
Via GlobeNewswire
News headline image
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine
From AC Immune SA
Via GlobeNewswire
News headline image
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune to Participate in Upcoming Investor Conferences
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
From AC Immune SA
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.